InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

15.02.2022 - Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative ...

Related Keywords

Serbia ,Germany ,United Kingdom ,Israel ,Italy ,Austria ,Canada ,France ,Spain ,Greece ,Canadian ,British ,Inmed Baymedica ,Catherine Sazdanoff ,Colin Clancy ,Erica Adams ,William Garner ,Inmed Pharmaceuticals ,Partner At Norton Rose Fulbright Canada ,Drug Administration ,Compensation Committee ,Baymedica Inc ,Audit Committee ,Exchange Commission ,Development Programs ,Almac Group United Kingdom ,Assurance Standards Council Of Canada ,Inmed President ,Almac Group ,Epidermolysis Bullosa ,Kindler Syndrome ,Modulates Neuroprotection ,Intraocular Pressure ,Potential Multi Target ,Therapeutic Intervention ,Biophysical Acta ,Investigational New Drug ,Patent Cooperation Treaty ,Treating Neuronal Disorders ,Janet Grove ,Norton Rose Fulbright Canada ,Assurance Standards Council ,British Columbia ,Corporate Governance ,Nominating Committee ,Nasdaq Capital Market ,Condensed Consolidated Interim Balance Sheets ,Condensed Consolidated Interim Statements ,Comprehensive Loss ,Cash Flows ,Pharmaceutical Programs ,Cannabinoid Manufacturing Capabilities ,Note Regarding Forward Looking Information ,Annual Report ,